GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » Net-Net Working Capital

IsoPlexis (IsoPlexis) Net-Net Working Capital : $-0.33 (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

IsoPlexis's Net-Net Working Capital for the quarter that ended in Dec. 2022 was $-0.33.

The industry rank for IsoPlexis's Net-Net Working Capital or its related term are showing as below:

ISO's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.22
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

IsoPlexis Net-Net Working Capital Historical Data

The historical data trend for IsoPlexis's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis Net-Net Working Capital Chart

IsoPlexis Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net-Net Working Capital
-0.91 -29.86 2.47 -0.33

IsoPlexis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.47 1.44 0.80 0.36 -0.33

Competitive Comparison of IsoPlexis's Net-Net Working Capital

For the Medical Devices subindustry, IsoPlexis's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IsoPlexis's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where IsoPlexis's Price-to-Net-Net-Working-Capital falls into.



IsoPlexis Net-Net Working Capital Calculation

IsoPlexis's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net-Net Working Capital(A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(37.465+0.75 * 4.502+0.5 * 27.516-67.801
-0-0)/39.6712
=-0.33

IsoPlexis's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2022 is calculated as

Net-Net Working Capital(Q: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(37.465+0.75 * 4.502+0.5 * 27.516-67.801
-0-0)/39.6712
=-0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


IsoPlexis  (NAS:ISO) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


IsoPlexis Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of IsoPlexis's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


IsoPlexis (IsoPlexis) Business Description

Traded in Other Exchanges
N/A
Address
35 North East Industrial Road, Branford, CT, USA, 06405
IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley officer: Chief Financial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay director, officer: Chief Executive Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii officer: SVP, GC & Secretary 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath director C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm director 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers director C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley director 396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho director, 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel officer: Chief Commercial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou officer: Chief Scientific Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar officer: VP, Finance 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc 10 percent owner 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003